Compare Danaher Corporation (DHR) vs Samsara Inc (IOT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs Samsara Inc — how do they compare? Danaher Corporation trades at $219.87 (market cap $152.87B), while Samsara Inc trades at $41.55 (market cap $24.14B). The key difference: Danaher Corporation is far larger — about 6.3× Samsara Inc's market cap, and Danaher Corporation pays a 0.74% dividend while Samsara Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Danaher Corporation for 69 Days and Samsara Inc for 19 Days on average.
| DHR | IOT | |
|---|---|---|
Market Cap | $152.87B | $24.14B |
Volume | 5,228,698 | 5,372,580 |
Sector | Health | Technology |
52-Week High | $242.05 | $45.22 |
52-Week Low | $161.91 | $24.25 |
Typical Hold Time | 69 Days | 19 Days |
Enterprise Value | $175.08B | $23.38B |
Dividend Yield | 0.74% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $217.46, down 0.47% on the day, with a bullish technical signal from moving averages and support at $214. The company shows strong profitability with a 58.51% gross margin and has beaten EPS estimates for three consecutive quarters. Recent news includes a declared $0.40 dividend payable in October 2026 and significant institutional buying, such as Bank of America's new $993.8 million stake in Q2 2026.
The outlook is positive with a consensus price target of $230.31, implying 5.9% upside, supported by 70% analyst buy ratings. Risks include elevated valuation multiples like a P/E of 38.76 and fluctuating cash flows, but earnings growth in biotechnology and steady revenue provide a solid foundation for investor confidence.
Samsara Inc. (IOT) trades at $41.22, up 1.75% today, with strong technical momentum and bullish moving average signals. The company demonstrates robust revenue growth, crossing $2.1B in ARR, and has beaten earnings estimates for three consecutive quarters. Recent partnerships and product launches highlight ongoing business expansion. However, valuation metrics remain elevated with a P/E of 274.8 and EV/EBITDA of 475.05, reflecting high growth expectations.
The outlook remains positive with 75% analyst buy ratings and a $51.15 consensus price target, suggesting 24% upside. Key risks include premium valuation sensitivity, cash flow pressure from increased investing, and the need to maintain high growth rates to justify current multiples. The stock's performance will depend on continued execution against guidance and margin expansion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About Samsara Inc
Samsara provides a connected operations cloud that uses IoT data to help businesses improve efficiency and safety. Its platform offers real-time visibility for fleet management, equipment monitoring, and industrial sites.
Read more on IOT →
